{"id":"candemore-plus-tab","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Candesartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone secretion, while amlodipine inhibits L-type calcium channels in vascular smooth muscle to promote vasodilation. Together, these complementary mechanisms provide synergistic antihypertensive effects with improved blood pressure control compared to monotherapy.","oneSentence":"Candemore Plus is a fixed-dose combination of candesartan cilexetil (an angiotensin II receptor blocker) and amlodipine (a calcium channel blocker) that reduces blood pressure through dual vasodilation and renin-angiotensin system inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:41.970Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT04521023","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-09-20","conditions":"Hypertension","enrollment":132},{"nctId":"NCT01682564","phase":"PHASE4","title":"To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2012-01","conditions":"Hypertension, Congestive Heart Failure","enrollment":169},{"nctId":"NCT01766505","phase":"PHASE4","title":"The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)","status":"TERMINATED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2012-06","conditions":"Hypertension","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":84,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Candemore Plus Tab","genericName":"Candemore Plus Tab","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Candemore Plus is a fixed-dose combination of candesartan cilexetil (an angiotensin II receptor blocker) and amlodipine (a calcium channel blocker) that reduces blood pressure through dual vasodilation and renin-angiotensin system inhibition. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}